Trial Outcomes & Findings for Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus (NCT NCT04510090)

NCT ID: NCT04510090

Last Updated: 2025-08-08

Results Overview

To assess safety and tolerability of EP547 following single and multiple oral administration

• Recruitment status: COMPLETED
• Study phase: PHASE1
• Target enrollment: 89 participants
• Primary outcome timeframe: Measured from Day 1 to End of Study or Early Termination (up to 3 weeks)
• Results posted on: 2025-08-08

Participant Flow

This study was conducted on 85 subjects at 4 sites in Australia and New Zealand. This study consisted of 7 segments: single ascending dose in healthy subjects (SAD-HS), multiple ascending dose in healthy subjects (MAD-HS), food effect in healthy subjects (FE-HS), single dose in subjects with cholestatic pruritus (SD-CP), multiple dose in subjects with cholestatic pruritus (MD-CP), single dose in subjects with uremic pruritus (SD-UP), and multiple dose in subjects with uremic pruritus (MD-UP).

A total of 89 subjects (85 unique subjects) participated in the study. SAD-HS n=40 MAD-HS n=24 FE-HS n=5 SD-CP n=5 SD-UP n=6 MD-CP n=3 MD-UP N=6 (4 subjects participated in both SD-UP and MD-UP)

Participant milestones

Measure	Placebo Participants in all segments received placebo matched to EP547.	EP547 20 mg Participants in MD-UP segment received 20 mg of EP547 QD for 7 days.	EP547 25 mg Participants in SAD-HS segment received a single 25 mg dose of EP547. Participants in MAD-HS segment received 25 mg of EP547 QD for 7 days.	EP547 30 mg Participants in MD-CP segment received 30 mg of EP547 QD for 7 days.	EP547 75 mg Participants in SAD-HS segment received a single 75 mg dose of EP547. Participants in MAD-HS segment received 75 mg of EP547 QD for 7 days. Participants in FE-HS segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period. Participants in SD-CP and SD-UP segments received a single 75 mg dose of EP547.	EP547 225 mg Participants in SAD-HS segment received a single 225 mg dose of EP547. Participants in MAD-HS segment received 225 mg of EP547 QD for 7 days.	EP547 450 mg Participants in SAD-HS segment received a single 450 mg dose of EP547.	EP547 675 mg Participants in SAD-HS segment received a single 675 mg dose of EP547.
SAD-HS STARTED	10	0	6	0	6	6	6	6
SAD-HS COMPLETED	10	0	6	0	6	6	6	6
SAD-HS NOT COMPLETED	0	0	0	0	0	0	0	0
MAD-HS STARTED	6	0	6	0	6	6	0	0
MAD-HS COMPLETED	6	0	6	0	6	6	0	0
MAD-HS NOT COMPLETED	0	0	0	0	0	0	0	0
FE-HS STARTED	0	0	0	0	5	0	0	0
FE-HS COMPLETED	0	0	0	0	4	0	0	0
FE-HS NOT COMPLETED	0	0	0	0	1	0	0	0
SD-CP STARTED	0	0	0	0	5	0	0	0
SD-CP COMPLETED	0	0	0	0	5	0	0	0
SD-CP NOT COMPLETED	0	0	0	0	0	0	0	0
SD-UP STARTED	0	0	0	0	6	0	0	0
SD-UP COMPLETED	0	0	0	0	6	0	0	0
SD-UP NOT COMPLETED	0	0	0	0	0	0	0	0
MD-CP STARTED	1	0	0	2	0	0	0	0
MD-CP COMPLETED	1	0	0	2	0	0	0	0
MD-CP NOT COMPLETED	0	0	0	0	0	0	0	0
MD-UP STARTED	2	4	0	0	0	0	0	0
MD-UP COMPLETED	2	4	0	0	0	0	0	0
MD-UP NOT COMPLETED	0	0	0	0	0	0	0	0

Reasons for withdrawal

Measure	Placebo Participants in all segments received placebo matched to EP547.	EP547 20 mg Participants in MD-UP segment received 20 mg of EP547 QD for 7 days.	EP547 25 mg Participants in SAD-HS segment received a single 25 mg dose of EP547. Participants in MAD-HS segment received 25 mg of EP547 QD for 7 days.	EP547 30 mg Participants in MD-CP segment received 30 mg of EP547 QD for 7 days.	EP547 75 mg Participants in SAD-HS segment received a single 75 mg dose of EP547. Participants in MAD-HS segment received 75 mg of EP547 QD for 7 days. Participants in FE-HS segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period. Participants in SD-CP and SD-UP segments received a single 75 mg dose of EP547.	EP547 225 mg Participants in SAD-HS segment received a single 225 mg dose of EP547. Participants in MAD-HS segment received 225 mg of EP547 QD for 7 days.	EP547 450 mg Participants in SAD-HS segment received a single 450 mg dose of EP547.	EP547 675 mg Participants in SAD-HS segment received a single 675 mg dose of EP547.
FE-HS Withdrawal by Subject	0	0	0	0	1	0	0	0

Baseline Characteristics

This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).

Baseline characteristics by cohort

Measure	Placebo n=19 Participants Participants in all segments received placebo matched to EP547.	EP547 20 mg n=4 Participants Participants in MD-UP segment received 20 mg of EP547 QD for 7 days.	EP547 25 mg n=12 Participants Participants in SAD-HS segment received a single 25 mg dose of EP547. Participants in MAD-HS segment received 25 mg of EP547 QD for 7 days.	EP547 30 mg n=2 Participants Participants in MD-CP segment received 30 mg of EP547 QD for 7 days.	EP547 75 mg n=28 Participants Participants in SAD-HS segment received a single 75 mg dose of EP547. Participants in MAD-HS segment received 75 mg of EP547 QD for 7 days. Participants in FE-HS segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period. Participants in SD-CP and SD-UP segments received a single 75 mg dose of EP547.	EP547 225 mg n=12 Participants Participants in SAD-HS segment received a single 225 mg dose of EP547. Participants in MAD-HS segment received 225 mg of EP547 QD for 7 days.	EP547 450 mg n=6 Participants Participants in SAD-HS segment received a single 450 mg dose of EP547.	EP547 675 mg n=6 Participants Participants in SAD-HS segment received a single 675 mg dose of EP547.	Total n=89 Participants Total of all reporting groups
Age, Continuous SAD-HS	27.3 Years STANDARD_DEVIATION 9.9 • n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	30.7 Years STANDARD_DEVIATION 12.3 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	32.5 Years STANDARD_DEVIATION 9.1 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	32.7 Years STANDARD_DEVIATION 11.1 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	30.2 Years STANDARD_DEVIATION 4.2 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	36.2 Years STANDARD_DEVIATION 4.2 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	31.2 Years STANDARD_DEVIATION 9.36 • n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Age, Continuous MAD-HS	32.8 Years STANDARD_DEVIATION 12.2 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	30.0 Years STANDARD_DEVIATION 13.5 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	42.0 Years STANDARD_DEVIATION 14.1 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	36.3 Years STANDARD_DEVIATION 16.3 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	35.3 Years STANDARD_DEVIATION 13.94 • n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Age, Continuous FE-HS	—	—	—	—	40.4 Years STANDARD_DEVIATION 13.4 • n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	40.4 Years STANDARD_DEVIATION 13.39 • n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Age, Continuous SD-CP	—	—	—	—	58.8 Years STANDARD_DEVIATION 15.7 • n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	58.8 Years STANDARD_DEVIATION 15.69 • n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Age, Continuous SD-UP	—	—	—	—	39.8 Years STANDARD_DEVIATION 10.3 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	39.8 Years STANDARD_DEVIATION 10.26 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Age, Continuous MD-CP	63.0 Years STANDARD_DEVIATION NA • n=1 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	46.0 Years STANDARD_DEVIATION 2.8 • n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	51.7 Years STANDARD_DEVIATION 10.02 • n=3 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Age, Continuous MD-UP	74.5 Years STANDARD_DEVIATION 4.9 • n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	41.8 Years STANDARD_DEVIATION 6.9 • n=4 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	—	—	52.7 Years STANDARD_DEVIATION 17.88 • n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male SAD-HS · Female	8 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	25 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male SAD-HS · Male	2 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	15 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male MAD-HS · Female	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	7 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male MAD-HS · Male	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	17 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male FE-HS · Female	—	—	—	—	3 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	3 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male FE-HS · Male	—	—	—	—	2 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	2 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male SD-CP · Female	—	—	—	—	3 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	3 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male SD-CP · Male	—	—	—	—	2 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	2 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male SD-UP · Female	—	—	—	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male SD-UP · Male	—	—	—	—	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male MD-CP · Female	1 Participants n=1 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	1 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	2 Participants n=3 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male MD-CP · Male	0 Participants n=1 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	1 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	1 Participants n=3 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male MD-UP · Female	1 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=4 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	—	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Sex: Female, Male MD-UP · Male	1 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=4 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	—	—	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SAD-HS · Hispanic or Latino	3 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	9 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SAD-HS · Not Hispanic or Latino	7 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	29 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SAD-HS · Unknown or Not Reported	0 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MAD-HS · Hispanic or Latino	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	1 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MAD-HS · Not Hispanic or Latino	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	22 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MAD-HS · Unknown or Not Reported	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	1 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) FE-HS · Hispanic or Latino	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) FE-HS · Not Hispanic or Latino	—	—	—	—	5 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	5 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) FE-HS · Unknown or Not Reported	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SD-CP · Hispanic or Latino	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SD-CP · Not Hispanic or Latino	—	—	—	—	5 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	5 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SD-CP · Unknown or Not Reported	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SD-UP · Hispanic or Latino	—	—	—	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SD-UP · Not Hispanic or Latino	—	—	—	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) SD-UP · Unknown or Not Reported	—	—	—	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MD-CP · Hispanic or Latino	0 Participants n=1 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	0 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	0 Participants n=3 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MD-CP · Not Hispanic or Latino	1 Participants n=1 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	1 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	2 Participants n=3 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MD-CP · Unknown or Not Reported	0 Participants n=1 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	1 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	1 Participants n=3 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MD-UP · Hispanic or Latino	0 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=4 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	—	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MD-UP · Not Hispanic or Latino	2 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	4 Participants n=4 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	—	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Ethnicity (NIH/OMB) MD-UP · Unknown or Not Reported	0 Participants n=2 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=4 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	—	—	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized SAD-HS Asian	2 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	6 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized SAD-HS Black or African American	0 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized SAD-HS White	5 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	6 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	5 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	25 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized SAD-HS American Indian or Alaska Native	1 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized SAD-HS Native Hawaiian or Pacific Islander	0 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized SAD-HS Other	2 Participants n=10 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	8 Participants n=40 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized MAD-HS Asian	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	5 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized MAD-HS Black or African American	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	0 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized MAD-HS White	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	4 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	3 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	12 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized MAD-HS American Indian or Alaska Native	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	0 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized MAD-HS Native Hawaiian or Pacific Islander	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	4 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized MAD-HS Other	0 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	2 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	1 Participants n=6 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	4 Participants n=24 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized FE-HS Asian	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized FE-HS Black or African American	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized FE-HS White	—	—	—	—	5 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	5 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized FE-HS American Indian or Native American	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized FE-HS Native Hawaiian or Pacific Islander	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).
Race/Ethnicity, Customized FE-HS Other	—	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).	—	—	—	0 Participants n=5 Participants • This study consisted of 7 segments: 1) single ascending dose in healthy subjects (SAD-HS), 2) multiple ascending dose in healthy subjects (MAD-HS), 3) food effect in healthy subjects (FE-HS), 4) single dose in subjects with cholestatic pruritus (SD-CP), 5) multiple dose in subjects with cholestatic pruritus (MD-CP), 6) single dose in subjects with uremic pruritus (SD-UP), and 7) multiple dose in subjects with uremic pruritus (MD-UP).

PRIMARY outcome

Timeframe: Measured from Day 1 to End of Study or Early Termination (up to 3 weeks)

Population: All safety analyses were based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo).

To assess safety and tolerability of EP547 following single and multiple oral administration

Outcome measures

Measure	Placebo n=19 Participants Participants in all segments received placebo matched to EP547.	EP547 20 mg n=4 Participants Participants in MD-UP segment received 20 mg of EP547 QD for 7 days.	EP547 25 mg n=12 Participants Participants in SAD-HS segment received a single 25 mg dose of EP547. Participants in MAD-HS segment received 25 mg of EP547 QD for 7 days.	EP547 30 mg n=2 Participants Participants in MD-CP segment received 30 mg of EP547 QD for 7 days.	EP547 75 mg n=28 Participants Participants in SAD-HS segment received a single 75 mg dose of EP547. Participants in MAD-HS segment received 75 mg of EP547 QD for 7 days. Participants in FE-HS segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period. Participants in SD-CP and SD-UP segments received a single 75 mg dose of EP547.	EP547 225 mg n=12 Participants Participants in SAD-HS segment received a single 225 mg dose of EP547. Participants in MAD-HS segment received 225 mg of EP547 QD for 7 days.	EP547 450 mg n=6 Participants Participants in SAD-HS segment received a single 450 mg dose of EP547.	EP547 675 mg n=6 Participants Participants in SAD-HS segment received a single 675 mg dose of EP547.
Incidence of Adverse Events FE-HS : Any TEAE	—	—	—	—	3 participants	—	—	—
Incidence of Adverse Events SAD-HS : Any TEAE	5 participants	—	5 participants	—	5 participants	3 participants	3 participants	4 participants
Incidence of Adverse Events SAD-HS : Any Serious TEAE	0 participants	—	0 participants	—	0 participants	0 participants	0 participants	0 participants
Incidence of Adverse Events SAD-HS : Any drug-related TEAE	0 participants	—	2 participants	—	1 participants	0 participants	1 participants	2 participants
Incidence of Adverse Events SAD-HS : Any TEAE leading to discontinuation of study drug	0 participants	—	0 participants	—	0 participants	0 participants	0 participants	0 participants
Incidence of Adverse Events MAD-HS : Any TEAE	3 participants	—	6 participants	—	4 participants	4 participants	—	—
Incidence of Adverse Events MAD-HS : Any Serious TEAE	0 participants	—	0 participants	—	0 participants	0 participants	—	—
Incidence of Adverse Events MAD-HS : Any drug-related TEAE	2 participants	—	5 participants	—	3 participants	2 participants	—	—
Incidence of Adverse Events MAD-HS : Any TEAE leading to discontinuation of study drug	0 participants	—	0 participants	—	0 participants	0 participants	—	—
Incidence of Adverse Events FE-HS : Any Serious TEAE	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events FE-HS : Any drug-related TEAE	—	—	—	—	1 participants	—	—	—
Incidence of Adverse Events FE-HS : Any TEAE leading to discontinuation of study drug	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events SD-CP : Any TEAE	—	—	—	—	4 participants	—	—	—
Incidence of Adverse Events SD-CP : Any Serious TEAE	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events SD-CP : Any drug-related TEAE	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events SD-CP : Any TEAE leading to discontinuation of study drug	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events SD-UP : Any TEAE	—	—	—	—	1 participants	—	—	—
Incidence of Adverse Events SD-UP : Any Serious TEAE	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events SD-UP : Any drug-related TEAE	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events SD-UP : Any TEAE leading to discontinuation of study drug	—	—	—	—	0 participants	—	—	—
Incidence of Adverse Events MD-CP : Any TEAE	1 participants	—	—	1 participants	—	—	—	—
Incidence of Adverse Events MD-CP : Any Serious TEAE	0 participants	—	—	0 participants	—	—	—	—
Incidence of Adverse Events MD-CP : Any drug-related TEAE	0 participants	—	—	1 participants	—	—	—	—
Incidence of Adverse Events MD-CP : Any TEAE leading to discontinuation of study drug	0 participants	—	—	0 participants	—	—	—	—
Incidence of Adverse Events MD-UP : Any TEAE	1 participants	2 participants	—	—	—	—	—	—
Incidence of Adverse Events MD-UP : Any Serious TEAE	0 participants	0 participants	—	—	—	—	—	—
Incidence of Adverse Events MD-UP : Any drug-related TEAE	0 participants	0 participants	—	—	—	—	—	—
Incidence of Adverse Events MD-UP : Any TEAE leading to discontinuation of study drug	0 participants	0 participants	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, and 12 hours post-dose on Day 1

Population: All PK analyses were based on the PK Population. For non-FE segments, the PK Population included all subjects who received ≥1 dose of EP547 and for whom a sufficient number of samples were available to determine at least 1 PK parameter. For FE segment, the PK Population included all randomized subjects who received ≥1 dose of EP547, had no protocol deviations affecting the PK variables of EP547, and for whom a sufficient number of samples were available to determine at least 1 PK parameter.

To evaluate the pharmacokinetics of single dose of EP547

Outcome measures

Measure	Placebo Participants in all segments received placebo matched to EP547.	EP547 20 mg n=4 Participants Participants in MD-UP segment received 20 mg of EP547 QD for 7 days.	EP547 25 mg n=12 Participants Participants in SAD-HS segment received a single 25 mg dose of EP547. Participants in MAD-HS segment received 25 mg of EP547 QD for 7 days.	EP547 30 mg n=2 Participants Participants in MD-CP segment received 30 mg of EP547 QD for 7 days.	EP547 75 mg n=28 Participants Participants in SAD-HS segment received a single 75 mg dose of EP547. Participants in MAD-HS segment received 75 mg of EP547 QD for 7 days. Participants in FE-HS segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period. Participants in SD-CP and SD-UP segments received a single 75 mg dose of EP547.	EP547 225 mg n=12 Participants Participants in SAD-HS segment received a single 225 mg dose of EP547. Participants in MAD-HS segment received 225 mg of EP547 QD for 7 days.	EP547 450 mg n=6 Participants Participants in SAD-HS segment received a single 450 mg dose of EP547.	EP547 675 mg n=6 Participants Participants in SAD-HS segment received a single 675 mg dose of EP547.
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 SAD-HS	—	—	1421.0 ng/mL Geometric Coefficient of Variation 29.4	—	6309.6 ng/mL Geometric Coefficient of Variation 19.3	17232.6 ng/mL Geometric Coefficient of Variation 17.6	27799.2 ng/mL Geometric Coefficient of Variation 29.8	36352.2 ng/mL Geometric Coefficient of Variation 38.3
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 MAD-HS	—	—	1506.6 ng/mL Geometric Coefficient of Variation 38.4	—	3973.4 ng/mL Geometric Coefficient of Variation 35.5	16954.8 ng/mL Geometric Coefficient of Variation 35.0	—	—
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 FE-HS (Fasted)	—	—	—	—	5780.3 ng/mL Geometric Coefficient of Variation 22.9	—	—	—
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 FE-HS (Fed)	—	—	—	—	3504.0 ng/mL Geometric Coefficient of Variation 30.0	—	—	—
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 SD-CP	—	—	—	—	5019.5 ng/mL Geometric Coefficient of Variation 31.7	—	—	—
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 SD-UP	—	—	—	—	3483.3 ng/mL Geometric Coefficient of Variation 75.0	—	—	—
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 MD-CP	—	—	—	1728.5 ng/mL Geometric Coefficient of Variation 93.7	—	—	—	—
Maximum Plasma Concentration [Cmax] After Single Dose of EP547 MD-UP	—	781.0 ng/mL Geometric Coefficient of Variation 54.6	—	—	—	—	—	—

SECONDARY outcome

Timeframe: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, and 24 hours post-dose on Day 7

Population: All PK analyses were based on the PK Population. For non-FE segments, the PK Population included all subjects who received ≥1 dose of EP547 and for whom a sufficient number of samples were available to determine at least 1 PK parameter. For FE segment, the PK Population included all randomized subjects who received ≥1 dose of EP547, had no protocol deviations affecting the PK variables of EP547, and for whom a sufficient number of samples were available to determine at least 1 PK parameter.

To evaluate the pharmacokinetics of multiple doses of EP547

Outcome measures

Measure	Placebo Participants in all segments received placebo matched to EP547.	EP547 20 mg n=4 Participants Participants in MD-UP segment received 20 mg of EP547 QD for 7 days.	EP547 25 mg n=6 Participants Participants in SAD-HS segment received a single 25 mg dose of EP547. Participants in MAD-HS segment received 25 mg of EP547 QD for 7 days.	EP547 30 mg n=2 Participants Participants in MD-CP segment received 30 mg of EP547 QD for 7 days.	EP547 75 mg n=6 Participants Participants in SAD-HS segment received a single 75 mg dose of EP547. Participants in MAD-HS segment received 75 mg of EP547 QD for 7 days. Participants in FE-HS segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period. Participants in SD-CP and SD-UP segments received a single 75 mg dose of EP547.	EP547 225 mg n=6 Participants Participants in SAD-HS segment received a single 225 mg dose of EP547. Participants in MAD-HS segment received 225 mg of EP547 QD for 7 days.	EP547 450 mg Participants in SAD-HS segment received a single 450 mg dose of EP547.	EP547 675 mg Participants in SAD-HS segment received a single 675 mg dose of EP547.
Maximum Plasma Concentration [Cmax] After Multiple Doses of EP547 MAD-HS	—	—	2834.7 ng/mL Geometric Coefficient of Variation 16.4	—	8760.7 ng/mL Geometric Coefficient of Variation 27.4	29613.1 ng/mL Geometric Coefficient of Variation 21.0	—	—
Maximum Plasma Concentration [Cmax] After Multiple Doses of EP547 MD-CP	—	—	—	3421.0 ng/mL Geometric Coefficient of Variation 27.8	—	—	—	—
Maximum Plasma Concentration [Cmax] After Multiple Doses of EP547 MD-UP	—	3192.7 ng/mL Geometric Coefficient of Variation 49.5	—	—	—	—	—	—

Adverse Events

SAD-HS Placebo

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

MAD-HS Placebo

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

MD-CP Placebo

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

MD-UP Placebo

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

MD-UP EP547 20 mg

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

SAD-HS EP547 25 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

MAD-HS EP547 25 mg

Serious events: 0 serious events

Other events: 6 other events

Deaths: 0 deaths

MD-CP EP547 30 mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

SAD-HS EP547 75 mg

Serious events: 0 serious events

Other events: 5 other events

Deaths: 0 deaths

MAD-HS EP547 75 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

FE-HS EP547 75 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

SD-CP EP547 75 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

SD-UP EP547 75 mg

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

SAD-HS EP547 225 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

MAD-HS EP547 225 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

SAD-HS EP547 450 mg

Serious events: 0 serious events

Other events: 3 other events

Deaths: 0 deaths

SAD-HS EP547 675 mg

Serious events: 0 serious events

Other events: 4 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Measure	SAD-HS Placebo n=10 participants at risk Participants in all segments received placebo matched to EP547.	MAD-HS Placebo n=6 participants at risk Participants in all segments received placebo matched to EP547.	MD-CP Placebo n=1 participants at risk Participants in this segment received placebo matched to EP547.	MD-UP Placebo n=2 participants at risk Participants in this segment received placebo matched to EP547.	MD-UP EP547 20 mg n=4 participants at risk Participants in this segment received 20 mg of EP547 QD for 7 days.	SAD-HS EP547 25 mg n=6 participants at risk Participants in this segment received a single 25 mg dose of EP547.	MAD-HS EP547 25 mg n=6 participants at risk Participants in this segment received 25 mg of EP547 QD for 7 days.	MD-CP EP547 30 mg n=2 participants at risk Participants in this segment received 30 mg of EP547 QD for 7 days.	SAD-HS EP547 75 mg n=6 participants at risk Participants in this segment received a single 75 mg dose of EP547.	MAD-HS EP547 75 mg n=6 participants at risk Participants in this segment received 75 mg of EP547 QD for 7 days.	FE-HS EP547 75 mg n=5 participants at risk Participants in this segment received a single 75 mg dose of EP547 under fed or fasted condition, separated by a washout period.	SD-CP EP547 75 mg n=5 participants at risk Participants in this segment received a single 75 mg dose of EP547.	SD-UP EP547 75 mg n=6 participants at risk Participants in this segment received a single 75 mg dose of EP547.	SAD-HS EP547 225 mg n=6 participants at risk Participants in this segment received a single 225 mg dose of EP547.	MAD-HS EP547 225 mg n=6 participants at risk Participants in this segment received 225 mg of EP547 QD for 7 days.	SAD-HS EP547 450 mg n=6 participants at risk Participants in this segment received a single 450 mg dose of EP547.	SAD-HS EP547 675 mg n=6 participants at risk Participants in this segment received a single 675 mg dose of EP547.
Metabolism and nutrition disorders Appetite disorder	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Blood and lymphatic system disorders Iron deficiency anaemia	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	25.0% 1/4 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Headache	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	83.3% 5/6 • Number of events 6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	50.0% 1/2 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	40.0% 2/5 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	50.0% 3/6 • Number of events 3 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Presyncope	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Dysgeusia	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Hypoaesthesia	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Dizziness	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	100.0% 1/1 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Head discomfort	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	50.0% 1/2 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Nervous system disorders Somnolence	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	20.0% 1/5 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Eye disorders Eyelid skin dryness	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	10.0% 1/10 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	20.0% 1/5 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Gastrointestinal disorders Nausea	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Gastrointestinal disorders Diarrhoea	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Gastrointestinal disorders Abdominal distension	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Gastrointestinal disorders Dyspepsia	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Gastrointestinal disorders Salivary gland pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Gastrointestinal disorders Lip dry	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Skin and subcutaneous tissue disorders Dry skin	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Skin and subcutaneous tissue disorders Erythema	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Skin and subcutaneous tissue disorders Pruritus	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Skin and subcutaneous tissue disorders Rash	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Skin and subcutaneous tissue disorders Urticaria	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	50.0% 1/2 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Skin and subcutaneous tissue disorders Dermatitis contact	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	20.0% 1/5 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Musculoskeletal and connective tissue disorders Arthralgia	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	20.0% 1/5 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Musculoskeletal and connective tissue disorders Myalgia	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Musculoskeletal and connective tissue disorders Neck pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	10.0% 1/10 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Renal and urinary disorders Pollakiuria	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Renal and urinary disorders Dysuria	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	25.0% 1/4 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Application site dermatitis	10.0% 1/10 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Application site irritation	10.0% 1/10 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Application site laceration	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Vessel puncture site swelling	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Fatigue	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	33.3% 2/6 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Application site rash	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Vessel puncture site bruise	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Vessel puncture site pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
General disorders Vessel puncture site haematoma	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	100.0% 1/1 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Injury, poisoning and procedural complications Muscle strain	10.0% 1/10 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Injury, poisoning and procedural complications Contusion	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	100.0% 1/1 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Injury, poisoning and procedural complications Procedural pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Injury, poisoning and procedural complications Skin abrasion	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	16.7% 1/6 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Injury, poisoning and procedural complications Thermal burn	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	20.0% 1/5 • Number of events 1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.
Injury, poisoning and procedural complications Vascular access site pain	0.00% 0/10 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/1 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/4 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	40.0% 2/5 • Number of events 2 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/5 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.	0.00% 0/6 • Measured from Day 1 to End of Study or Early Termination (up to 3 weeks) Adverse events reporting based on the Safety Population, which included all subjects who received at least one dose of study drug (EP547 or placebo). All AE summaries restricted to treatment-emergent adverse events only.

Additional Information

Kristin Taylor, Sr VP, Head of Clinical Development

Escient Pharmaceuticals

Phone: (858) 617-8220

Email: clinicaltrials@escientpharma.com

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: LTE60